Kirstine Brown‐Frandsen

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun et al. · New England Journal of Medicine · 2023 · 2.1K citations · Full text

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design

Donna H. Ryan, Ildiko Lingvay, Helen M. Colhoun et al. · American Heart Journal · 2020 · 229 citations · Full text

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Darren K. McGuire, Nikolaus Marx, Sharon L. Mulvagh et al. · New England Journal of Medicine · 2025 · 194 citations

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Helen M. Colhoun, Ildiko Lingvay, Paul Brown et al. · Nature Medicine · 2024 · 168 citations · Full text

Semaglutide for cardiovascular event reduction in people with overweight or obesity: <scp>SELECT</scp> study baseline characteristics

Ildiko Lingvay, Kirstine Brown‐Frandsen, Helen M. Colhoun et al. · Obesity · 2022 · 95 citations · Full text